Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies–
WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience spanning multiple therapeutic areas, including autoimmune diseases, early- and late-stage clinical development, and commercialization at both large and smaller emerging growth companies.
'I am delighted to welcome Lisa to the Zenas leadership team as we advance obexelimab through Phase 2 and Phase 3 clinical trials in an effort to meaningfully impact the lives of patients with autoimmune diseases, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus,' said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. 'Zenas will benefit from Lisa's proven leadership and extensive drug development experience, including her successful track record of moving multiple products through development and global regulatory approvals.'
'It is an exciting time to join Zenas, as we approach multiple meaningful clinical trial results, and I am eager to help the company achieve its objectives and bring obexelimab to patients with autoimmune diseases throughout the world,' said Dr. von Moltke. 'I believe obexelimab's unique ability to inhibit the activity of B cells without depleting them, along with its demonstrated clinical activity and self-administered, subcutaneous injection regimen, represent a compelling profile and opportunity to potentially address the challenges that still exist in treating patients with chronic autoimmune diseases, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus.'
Dr. von Moltke most recently served as CMO at Seres Therapeutics with functional oversight of clinical development, sciences and operations, and regulatory and medical affairs. Prior to Seres, Dr. von Moltke served in roles of increasing responsibility at Alkermes, Inc., culminating as Senior Vice President and Head of Clinical Development. Before joining Alkermes, Dr. von Moltke was Vice President, Clinical and Exploratory Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head of CEP for Japan and China. Earlier in her career, Dr. von Moltke was Head, Translational Medicine at Millennium: The Takeda Oncology Company. Dr. von Moltke was a practicing physician and completed a fellowship in clinical pharmacology at Tufts University School of Medicine and had an academic career in pharmacology and developmental therapeutics that spanned fifteen years. She has also served as President of the American College of Clinical Pharmacology and as Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. von Moltke earned a B.A. at Wellesley College and an M.D. from Michigan State University, College of Human Medicine, and she is a current member of the Board of Directors at Cara Therapeutics, Inc.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas' lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab's unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn.
Forward looking statements
This press release contains 'forward-looking statements' which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning Zenas's plans, objectives, expectations and intentions; advancing our clinical trials with obexelimab and the expected results from the phase 3 INDIGO trial, the MoonStone trial and the SunStone trial; and obexelimab's potential benefits and opportunity to potentially address the challenges that still exist in treating patients with chronic autoimmune diseases, including IgG4-RD, MS and SLE. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company's actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company's limited operating history, incurrence of substantial losses since the Company's inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company's need for substantial additional financing to achieve the Company's goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company's current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company's product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies, many of which already have approved therapies in the Company's current indications; the Company's ability to realize the benefits of the Company's current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company's ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company's dependence on the services of the Company's senior management and other clinical and scientific personnel, and the Company's ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company's ability to grow the Company's organization, and manage the Company's growth and expansion of the Company's operations; risks related to the manufacturing of the Company's product candidates, which is complex, and the risk that the Company's third-party manufacturers may encounter difficulties in production; the Company's ability to obtain and maintain sufficient intellectual property protection for the Company's product candidates or any future product candidates the Company may develop; the Company's reliance on third parties to conduct the Company's preclinical studies and clinical trials; the Company's compliance with the Company's obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company's product candidates; risks related to the operations of the Company's suppliers, many of which are located outside of the United States, including the Company's current sole contract manufacturing organization for drug substance and drug product, WuXi Biologics (Hong Kong) Limited, which is located in China; and other risks and uncertainties described in the section 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain, speak only as of the date of this press release and may prove incorrect. These statements are based upon information available to the Company as of the date of this press release and while the Company believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that the Company has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company's control, these forward-looking statements should not be relied upon as guarantees of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
The Zenas BioPharma word mark, logo mark, and the 'lightning bolt' design are trademarks of Zenas BioPharma, Inc. or its affiliated companies.
Investor Contact:
Matthew Osborne
Media Contact:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Those who invested in Automatic Data Processing (NASDAQ:ADP) five years ago are up 135%
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you can make far more than 100% on a really good stock. For example, the Automatic Data Processing, Inc. (NASDAQ:ADP) share price has soared 112% in the last half decade. Most would be very happy with that. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During five years of share price growth, Automatic Data Processing achieved compound earnings per share (EPS) growth of 11% per year. This EPS growth is lower than the 16% average annual increase in the share price. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). Dive deeper into Automatic Data Processing's key metrics by checking this interactive graph of Automatic Data Processing's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Automatic Data Processing, it has a TSR of 135% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments! It's good to see that Automatic Data Processing has rewarded shareholders with a total shareholder return of 26% in the last twelve months. That's including the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 19% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Before spending more time on Automatic Data Processing it might be wise to click here to see if insiders have been buying or selling shares. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Those who invested in LPL Financial Holdings (NASDAQ:LPLA) five years ago are up 437%
Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly amazing gains over the years. Just think about the savvy investors who held LPL Financial Holdings Inc. (NASDAQ:LPLA) shares for the last five years, while they gained 422%. And this is just one example of the epic gains achieved by some long term investors. It's also good to see the share price up 11% over the last quarter. But this move may well have been assisted by the reasonably buoyant market (up 5.3% in 90 days). Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During five years of share price growth, LPL Financial Holdings achieved compound earnings per share (EPS) growth of 15% per year. This EPS growth is slower than the share price growth of 39% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. And that's hardly shocking given the track record of growth. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of LPL Financial Holdings' earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of LPL Financial Holdings, it has a TSR of 437% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! It's nice to see that LPL Financial Holdings shareholders have received a total shareholder return of 36% over the last year. That's including the dividend. Having said that, the five-year TSR of 40% a year, is even better. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 2 warning signs we've spotted with LPL Financial Holdings . If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Chime versus SoFi: Which Is the Better Fintech Stock Right Now?
Chime operates an online banking platform that is similar to SoFi. SoFi is acquiring new members, increasing revenue, and accelerating profit at a pace superior to the competition. 10 stocks we like better than SoFi Technologies › It's been a hot couple of weeks for the fintech sector. Digital banking platform (NASDAQ: CHYM) and stablecoin operator Circle (NYSE: CRCL) both completed initial public offerings (IPOs) in which shares of both companies soared. While artificial intelligence (AI) is still the biggest megatrend fueling the stock market right now, the back-to-back IPOs from Circle and Chime have brought some renewed interest to the financial services arena. Given the overlapping business models of Chime and SoFi Technologies (NASDAQ: SOFI), another budding neobank, investors may be wondering which stock is the better buy right now. Let's assess Chime and SoFi from both an operational and valuation perspective. After doing so, I think smart investors will be able to determine a clear winner between the two digital banking platforms. SoFi offers many of the same financial services products that you may see at traditional banks. By offering lending, insurance, and investment management, SoFi has proven that it can compete with legacy banking providers by offering a similar, diversified portfolio of products. The main differentiator between SoFi and most of its competitors is that the company operates entirely online and lacks physical brick-and-mortar infrastructure. By creating a one-stop shop for financial services, SoFi is offering a level of convenience that is hard to match. In turn, SoFi is not only able to keep its customers loyal to the platform, but also has leveraged its comprehensive ecosystem by cross-selling additional services to existing members. SoFi refers to this strategy as its financial services productivity loop -- essentially building a model in which the lifetime value of customers increases over time, ultimately creating a competitive advantage over incumbent providers. At the end of the first quarter, SoFi boasted 10.9 million customers on its platform that use a total of 15.9 million products. This implies that each user in SoFi's network is using 1.4 products on average. As the chart above illustrates, SoFi's business model is paying off in spades, underscored by accelerating revenue growth and a transition to consistent profitability. While SoFi's business is rocking, Chime doesn't appear too far behind. In the table below, I've summarized a number of financial metrics and key performance indicators for SoFi and Chime. Category SoFi Chime Revenue -- Trailing 12-month ($) $2.8 billion $1.8 billion Members 10.9 million 8.6 million 3-year membership compound annual growth rate (CAGR) 41.3% 22.3% Net income (Trailing 12-Months) $482 million ($28.3) million Market capitalization (as of June 18) $17 billion $10.6 billion Data source: SoFi Investor Relations and Chime S-1 Filing. The obvious takeaway from the figures above is that SoFi is a larger business than Chime in terms of revenue. This is not entirely surprising, given that SoFi's platform boasts more than 2 million more members than Chime. The more subtle factor that I'd like to point out is that SoFi is far more profitable than Chime. Perhaps the biggest contributor to SoFi's profitability profile is the rate at which it is acquiring new members relative to the competition. Per the table above, SoFi's three-year compound annual growth rate (CAGR) for user acquisition is almost double that of Chime's. By onboarding more users, SoFi has been able to more quickly monetize these members and command superior unit economics compared to its peers. While Chime's growth is impressive, the company lags behind SoFi on a number of critical metrics. While I suspect that Chime may see a brief uptick in its operations thanks to the notoriety that came with the IPO, I question if the company will ever eclipse SoFi's size. Although SoFi is a bit pricey compared to traditional bank and financial services stocks based on its price-to-earnings (P/E) ratio, I think the shares deserve a premium due to the company's technology-first platform. I see SoFi growing into its valuation thanks to future earnings growth. If I had to choose between the two digital bank stocks explored here, I'd pick SoFi without thinking twice. Before you buy stock in SoFi Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoFi Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Wells Fargo is an advertising partner of Motley Fool Money. Adam Spatacco has positions in SoFi Technologies. The Motley Fool has positions in and recommends JPMorgan Chase and PayPal. The Motley Fool recommends Capital One Financial and recommends the following options: long January 2027 $42.50 calls on PayPal and short June 2025 $77.50 calls on PayPal. The Motley Fool has a disclosure policy. Chime versus SoFi: Which Is the Better Fintech Stock Right Now? was originally published by The Motley Fool Sign in to access your portfolio
